166 related articles for article (PubMed ID: 32423566)
1. Lipid efflux mechanisms, relation to disease and potential therapeutic aspects.
Castaño D; Rattanasopa C; Monteiro-Cardoso VF; Corlianò M; Liu Y; Zhong S; Rusu M; Liehn EA; Singaraja RR
Adv Drug Deliv Rev; 2020; 159():54-93. PubMed ID: 32423566
[TBL] [Abstract][Full Text] [Related]
2. HDL and Reverse Cholesterol Transport.
Ouimet M; Barrett TJ; Fisher EA
Circ Res; 2019 May; 124(10):1505-1518. PubMed ID: 31071007
[TBL] [Abstract][Full Text] [Related]
3. Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment.
Frambach SJCM; de Haas R; Smeitink JAM; Rongen GA; Russel FGM; Schirris TJJ
Pharmacol Rev; 2020 Jan; 72(1):152-190. PubMed ID: 31831519
[TBL] [Abstract][Full Text] [Related]
4. New insights into the regulation of HDL metabolism and reverse cholesterol transport.
Lewis GF; Rader DJ
Circ Res; 2005 Jun; 96(12):1221-32. PubMed ID: 15976321
[TBL] [Abstract][Full Text] [Related]
5. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins.
Borggreve SE; De Vries R; Dullaart RP
Eur J Clin Invest; 2003 Dec; 33(12):1051-69. PubMed ID: 14636288
[TBL] [Abstract][Full Text] [Related]
6. Age-associated decrease of high-density lipoprotein-mediated reverse cholesterol transport activity.
Berrougui H; Khalil A
Rejuvenation Res; 2009 Apr; 12(2):117-26. PubMed ID: 19405812
[TBL] [Abstract][Full Text] [Related]
7. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein.
Favari E; Lee M; Calabresi L; Franceschini G; Zimetti F; Bernini F; Kovanen PT
J Biol Chem; 2004 Mar; 279(11):9930-6. PubMed ID: 14701812
[TBL] [Abstract][Full Text] [Related]
8. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
[TBL] [Abstract][Full Text] [Related]
9. Sphingolipid synthetic pathways are major regulators of lipid homeostasis.
Worgall TS
Adv Exp Med Biol; 2011; 721():139-48. PubMed ID: 21910087
[TBL] [Abstract][Full Text] [Related]
10. Shuttle/sink model composed of β-cyclodextrin and simvastatin-loaded discoidal reconstituted high-density lipoprotein for enhanced cholesterol efflux and drug uptake in macrophage/foam cells.
He J; Yang Y; Zhou X; Zhang W; Liu J
J Mater Chem B; 2020 Feb; 8(7):1496-1506. PubMed ID: 31999290
[TBL] [Abstract][Full Text] [Related]
11. ABC Transporters, Cholesterol Efflux, and Implications for Cardiovascular Diseases.
Wang N; Westerterp M
Adv Exp Med Biol; 2020; 1276():67-83. PubMed ID: 32705595
[TBL] [Abstract][Full Text] [Related]
12. Lipid disorders and their relevance to outcomes in chronic kidney disease.
Vaziri ND; Norris K
Blood Purif; 2011; 31(1-3):189-96. PubMed ID: 21228589
[TBL] [Abstract][Full Text] [Related]
13. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
Vaziri ND
J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
[TBL] [Abstract][Full Text] [Related]
14. HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target.
Bhatt A; Rohatgi A
Curr Atheroscler Rep; 2016 Jan; 18(1):2. PubMed ID: 26710794
[TBL] [Abstract][Full Text] [Related]
15. Rate-limiting factors of cholesterol efflux in reverse cholesterol transport: acceptors and donors.
Fu Y
Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):703-9. PubMed ID: 20374257
[TBL] [Abstract][Full Text] [Related]
16. microRNAs in lipoprotein metabolism and cardiometabolic disorders.
Rotllan N; Price N; Pati P; Goedeke L; Fernández-Hernando C
Atherosclerosis; 2016 Mar; 246():352-60. PubMed ID: 26828754
[TBL] [Abstract][Full Text] [Related]
17. HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export.
Du XM; Kim MJ; Hou L; Le Goff W; Chapman MJ; Van Eck M; Curtiss LK; Burnett JR; Cartland SP; Quinn CM; Kockx M; Kontush A; Rye KA; Kritharides L; Jessup W
Circ Res; 2015 Mar; 116(7):1133-42. PubMed ID: 25589556
[TBL] [Abstract][Full Text] [Related]
18. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins.
Wang N; Lan D; Chen W; Matsuura F; Tall AR
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9774-9. PubMed ID: 15210959
[TBL] [Abstract][Full Text] [Related]
19. HDL cholesterol efflux capacity and incident cardiovascular events.
Rohatgi A; Khera A; Berry JD; Givens EG; Ayers CR; Wedin KE; Neeland IJ; Yuhanna IS; Rader DR; de Lemos JA; Shaul PW
N Engl J Med; 2014 Dec; 371(25):2383-93. PubMed ID: 25404125
[TBL] [Abstract][Full Text] [Related]
20. Micro-RNAs and High-Density Lipoprotein Metabolism.
Canfrán-Duque A; Lin CS; Goedeke L; Suárez Y; Fernández-Hernando C
Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1076-84. PubMed ID: 27079881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
